MedPath

Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Phase 3
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2005-09-05
Last Posted Date
2009-02-09
Lead Sponsor
University of Ulm
Target Recruit Count
400
Registration Number
NCT00146120
Locations
🇩🇪

I. Medical Department, City Hospital München-Schwabing, München, Germany

🇩🇪

Centre of Interial Medicine, University of Göttingen, Göttingen, Germany

🇩🇪

Medical Department III of Hematology and Oncology, General Hospital Altona, Hamburg, Germany

and more 19 locations

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Phase 3
Completed
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
Drug: Rituximab
Drug: Cisplatine
Drug: Etoposide
Drug: Carboplatine
Drug: Cytosine Arabinoside
Drug: Ifosfamide + Mesna
Drug: Dexamethasone
Procedure: Autologous Stem Cell Transplantation
Drug: BCNU
Drug: Cytarabine
Drug: Melphalan
First Posted Date
2005-08-30
Last Posted Date
2019-08-28
Lead Sponsor
Lymphoma Study Association
Target Recruit Count
481
Registration Number
NCT00137995
Locations
🇮🇱

Israel Society of Hematology, Tel-Hashomer, Israel

🇨🇭

Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland

🇫🇮

Hospital district of south west Finland, Turku, Finland

and more 7 locations

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Phase 3
Completed
Conditions
Localized Osteosarcoma
Metastatic Osteosarcoma
Interventions
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Methotrexate
Drug: Etoposide
Other: Quality-of-Life Assessment
Biological: Peginterferon Alfa-2b
Drug: Ifosfamide
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery
First Posted Date
2005-08-24
Last Posted Date
2023-06-07
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1334
Registration Number
NCT00134030
Locations
🇺🇸

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States

and more 215 locations

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2005-08-17
Last Posted Date
2008-11-14
Lead Sponsor
Japan Adult Leukemia Study Group
Target Recruit Count
240
Registration Number
NCT00131027
Locations
🇯🇵

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

First Posted Date
2005-08-03
Last Posted Date
2013-05-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
10
Registration Number
NCT00126191
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Leukemia
First Posted Date
2005-07-28
Last Posted Date
2013-05-03
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT00124644
Locations
🇺🇸

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

First Posted Date
2005-07-11
Last Posted Date
2021-11-17
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
524
Registration Number
NCT00118209
Locations
🇺🇸

Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

🇺🇸

Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States

🇺🇸

Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States

and more 44 locations

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
Drug: tipifarnib
Drug: etoposide
First Posted Date
2005-06-03
Last Posted Date
2013-01-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
100
Registration Number
NCT00112853
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Phase 2
Active, not recruiting
Conditions
Retinoblastoma
Interventions
Biological: filgrastim
Drug: Carboplatin
Drug: Cyclosporine
Drug: Etoposide
Drug: vincristine sulfate
Procedure: cryosurgery
Procedure: laser therapy
First Posted Date
2005-05-04
Last Posted Date
2024-04-17
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
71
Registration Number
NCT00110110
Locations
🇨🇱

Hospital San Juan de Dios, Santiago, Chile

🇨🇦

Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada

🇮🇳

Sankara Nethralaya Super Specialty Clinic, Chennai, India

and more 3 locations

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

First Posted Date
2005-05-04
Last Posted Date
2014-10-01
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
34
Registration Number
NCT00109928
Locations
🇺🇸

Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States

🇺🇸

Sparrow Regional Cancer Center, Lansing, Michigan, United States

🇺🇸

Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States

and more 73 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy